Novel Genetic Loci Associated with the Plasma Triglyceride Response to an Omega-3 Fatty Acid Supplementation

Journal of Nutrigenetics and Nutrigenomics

Volumn 9, Issue 1, 2016, Pages 1-11

  Vallée Marcotte, Bastien ^a   Cormier, Hubert ^a   Guénard, Frédéric ^a   Rudkowska, Iwona ^b   Lemieux, Simone ^a   Couture, Patrick ^a,b   Vohl, Marie Claude ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Gene diet interactions; Genome wide association study; Nutrigenetics; Omega 3 fatty acids; Plasma lipid levels

Indexed keywords

DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; LIPID; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; CALMODULIN BINDING PROTEIN; GLYCOPROTEIN; HOMEODOMAIN PROTEIN; IQCJ PROTEIN, HUMAN; NEUREXOPHILIN; NEUROPEPTIDE; PHF17 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

3' UNTRANSLATED REGION; ADULT; ALLELE; ARTICLE; BODY MASS; DENSITY; DIET SUPPLEMENTATION; FEMALE; GENE; GENE FREQUENCY; GENE INTERACTION; GENE LOCUS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMAN; INTRON; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DIETARY SUPPLEMENT; GENETICS; NUTRIGENOMICS; ONCOGENE MYB; YOUNG ADULT;

ADULT; CALMODULIN-BINDING PROTEINS; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; FISH OILS; GENES, MYB; GENOME-WIDE ASSOCIATION STUDY; GLYCOPROTEINS; HOMEODOMAIN PROTEINS; HUMANS; MALE; NEUROPEPTIDES; NUTRIGENOMICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRIGLYCERIDES; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84966431230     PISSN: 16616499     EISSN: 16616758     Source Type: Journal    
DOI: 10.1159/000446024     Document Type: Article

References (39)

1. Marik PE, Varon J: Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 2009; 32: 365-372.
2. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S: Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011; 123: 2292-2333.
3. Cormier H, Rudkowska I, Paradis AM, Thifault E, Garneau V, Lemieux S, Couture P, Vohl MC: Association between polymorphisms in the fatty acid desaturase gene cluster and the plasma triacylglycerol response to an n-3 PUFA supplementation. Nutrients 2012; 4: 1026-1041.
4. Caslake MJ, Miles EA, Kofler BM, Lietz G, Curtis P, Armah CK, Kimber AC, Grew JP, Farrell L, Stannard J, Napper FL, Sala-Vila A, West AL, Mathers JC, Packard C, Williams CM, Calder PC, Minihane AM: Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN study. Am J Clin Nutr 2008; 88: 618-629.
5. Masson LF, McNeill G, Avenell A: Genetic variation and the lipid response to dietary intervention: a systematic review. Am J Clin Nutr 2003; 77: 1098-1111.
6. Minihane AM, Khan S, Leigh-Firbank EC, Talmud P, Wright JW, Murphy MC, Griffin BA, Williams CM: APOE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler Thromb Vasc Biol 2000; 20: 1990-1997.
7. Tai ES, Demissie S, Cupples LA, Corella D, Wilson PW, Schaefer EJ, Ordovas JM: Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2002; 22: 805-810.
8. Lindi V, Schwab U, Louheranta A, Laakso M, Vessby B, Hermansen K, Storlien L, Riccardi G, Rivellese A: Impact of the Pro12Ala polymorphism of the PPAR-γ2 gene on serum triacylglycerol response to n-3 fatty acid supplementation. Mol Genet Metab 2003; 79: 52-60.
9. Thifault E, Cormier H, Bouchard-Mercier A, Rudkowska I, Paradis AM, Garneau V, Ouellette C, Lemieux S, Couture P, Vohl MC: Effects of age, sex, body mass index and APOE genotype on cardiovascular biomarker response to an n-3 polyunsaturated fatty acid supplementation. J Nutrigenet Nutrigenomics 2013; 6: 73-82.
10. Rudkowska I, Guenard F, Julien P, Couture P, Lemieux S, Barbier O, Calder PC, Minihane AM, Vohl MC: Genomewide association study of the plasma triglyceride response to an n-3 polyunsaturated fatty acid supplementation. J Lipid Res 2014; 55: 1245-1253.
11. Kwasnicka-Crawford DA, Carson AR, Scherer SW: IQCJ-SCHIP1, a novel fusion transcript encoding a calmodulin-binding IQ motif protein. Biochem Biophys Res Commun 2006; 350: 890-899.
12. Martin PM, Carnaud M, Garcia del CG, Irondelle M, Irinopoulou T, Girault JA, Dargent B, Goutebroze L: Schwannomin-interacting protein-1 isoform IQCJ-SCHIP-1 is a late component of nodes of Ranvier and axon initial segments. J Neurosci 2008; 28: 6111-6117.
13. Missler M, Hammer RE, Sudhof TC: Neurexophilin binding to α-neurexins. A single LNS domain functions as an independently folding ligand-binding unit. J Biol Chem 1998; 273: 34716-34723.
14. Missler M, Sudhof TC: Neurexophilins form a conserved family of neuropeptide-like glycoproteins. J Neurosci 1998; 18: 3630-3638.
15. Reissner C, Stahn J, Breuer D, Klose M, Pohlentz G, Mormann M, Missler M: Dystroglycan binding to α-neurexin competes with neurexophilin-1 and neuroligin in the brain. J Biol Chem 2014; 289: 27585-27603.
16. Zhou MI, Foy RL, Chitalia VC, Zhao J, Panchenko MV, Wang H, Cohen HT: Jade-1, a candidate renal tumor suppressor that promotes apoptosis. Proc Natl Acad Sci USA 2005; 102: 11035-11040.
17. Doyon Y, Cayrou C, Ullah M, Landry AJ, Cote V, Selleck W, Lane WS, Tan S, Yang XJ, Cote J: ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell 2006; 21: 51-64.
18. Foy RL, Song IY, Chitalia VC, Cohen HT, Saksouk N, Cayrou C, Vaziri C, Cote J, Panchenko MV: Role of Jade-1 in the histone acetyltransferase (HAT) HBO1 complex. J Biol Chem 2008; 283: 28817-28826.
19. Siriwardana NS, Meyer R, Havasi A, Dominguez I, Panchenko MV: Cell cycle-dependent chromatin shuttling of HBO1-JADE1 histone acetyl transferase (HAT) complex. Cell Cycle 2014; 13: 1885-1901.
20. Vanhee S, De MK, Van CY, Verstichel G, Van RN, Menten B, Velghe I, Philippe J, De BD, Lambrecht BN, Taghon T, Leclercq G, Kerre T, Vandekerckhove B: In vitro human embryonic stem cell hematopoiesis mimics MYB-independent yolk sac hematopoiesis. Haematologica 2015; 100: 157-166.
21. Sarvaiya PJ, Schwartz JR, Hernandez CP, Rodriguez PC, Vedeckis WV: Role of c-Myb in the survival of pre B-cell acute lymphoblastic leukemia and leukemogenesis. Am J Hematol 2012; 87: 969-976.
22. Costa AF, Altemani A, Garcia-Inc, Fresno F, Suarez C, Llorente JL, Hermsen M: Analysis of Myb oncogene in transformed adenoid cystic carcinomas reveals distinct pathways of tumor progression. Lab Invest 2014; 94: 692-702.
23. Burstein M, Samaille J: On a rapid determination of the cholesterol bound to the serum α-and β-lipoproteins (in French). Clin Chim Acta 1960; 5: 609.
24. McNamara JR, Schaefer EJ: Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 1987; 166: 1-8.
25. Leiter LA, Betteridge DJ, Farnier M, Guyton JR, Lin J, Shah A, Johnson-Levonas AO, Brudi P: Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes Metab 2011; 13: 615-628.
26. Kraja AT, Borecki IB, Tsai MY, Ordovas JM, Hopkins PN, Lai CQ, Frazier-Wood AC, Straka RJ, Hixson JE, Province MA, Arnett DK: Genetic analysis of 16 NMR-lipoprotein fractions in humans, the GOLDN study. Lipids 2013; 48: 155-165.
27. Kiefer D, Pantuso T: Omega-3 fatty acids: an update emphasizing clinical use. Agro Food Ind Hi Tech 2012; 23: 10-13.
28. Delerive P, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001; 169: 453-459.
29. Bragt MC, Mensink RP: Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects. Nutr Metab Cardiovasc Dis 2012; 22: 966-973.
30. Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B: Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 2011; 217: 492-498.
31. Frazier-Wood AC, Aslibekyan S, Borecki IB, Hopkins PN, Lai CQ, Ordovas JM, Straka RJ, Tiwari HK, Arnett DK: Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate. Pharmacogenet Genomics 2012; 22: 750-757.
32. Kondo A, Muranaka Y, Ohta I, Notsu K, Manabe M, Kotani K, Saito K, Maekawa M, Kanno T: Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL. Clin Chem 2001; 47: 893-900.
33. Comuzzie AG, Cole SA, Laston SL, Voruganti VS, Haack K, Gibbs RA, Butte NF: Novel genetic loci identified for the pathophysiology of childhood obesity in the hispanic population. PLoS One 2012; 7:e51954.
34. Zhao L, Ye P, Gonda TJ: The MYB proto-oncogene suppresses monocytic differentiation of acute myeloid leukemia cells via transcriptional activation of its target gene GFI1. Oncogene 2014; 33: 4442-4449.
35. Gross CM, Kramer J, Pfeufer A, Dietz R, Gessner R, Praus M: The intron 6 G/T polymorphism of c-myb oncogene and the risk for coronary in-stent restenosis. Basic Res Cardiol 2004; 99: 309-314.
36. Lai WK, Kan MY: Homocysteine-induced endothelial dysfunction. Ann Nutr Metab 2015; 67: 1-12.
37. Melen E, Himes BE, Brehm JM, Boutaoui N, Klanderman BJ, Sylvia JS, Lasky-Su J: Analyses of shared genetic factors between asthma and obesity in children. J Allergy Clin Immunol 2010; 126: 631-637.
38. Xu H, Inouye M, Hines ER, Collins JF, Ghishan FK: Transcriptional regulation of the human NaPi-IIb cotrans-porter by EGF in Caco-2 cells involves c-myb. Am J Physiol Cell Physiol 2003; 284:C1262-C1271.
39. Chen Y, Liu J, Xu H, Luo Z, Zhang C: Overexpression of the c-myb but not its leukemogenic mutant DNA-binding domain increased adipogenic differentiation in mesenchymal stem cells. Biochem Biophys Res Commun 2011; 407: 202-206.